

Resource Summary Report

Generated by PRECISE-TBI on Aug 9, 2026

Ms CD3 MolCpx BUV805 17A2 50ug

RRID:AB_2871285

Type: Antibody

Proper Citation

BD Biosciences Cat# 741982, RRID:AB_2871285

Antibody Information

URL: http://antibodyregistry.org/AB_2871285

Proper Citation: BD Biosciences Cat# 741982, RRID:AB_2871285

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Ms CD3 MolCpx BUV805 17A2 50ug

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: 17A2

Antibody ID: AB_2871285

Vendor: BD Biosciences

Catalog Number: 741982

Record Creation Time: 20250820T030756+0000

Record Last Update: 20250820T152623+0000

Ratings and Alerts

No rating or validation information has been found for Ms CD3 MolCpx BUV805 17A2 50ug.

No alerts have been found for Ms CD3 MolCpx BUV805 17A2 50ug.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Corgnac S, et al. (2025) TGF- β and IL-12 conversely orchestrate the formation of CD103+ CD8 tumor-resident memory T cells to regulate response to therapeutic cancer vaccine. iScience, 28(8), 113147.

Zhanzak Z, et al. (2025) Identification of indirect CD4+ T cell epitopes associated with transplant rejection provides a target for donor-specific tolerance induction. Immunity, 58(2), 448.

Jacobs MME, et al. (2024) Trained immunity is regulated by T cell-induced CD40-TRAF6 signaling. Cell reports, 43(9), 114664.

Darragh LB, et al. (2024) Sensory nerve release of CGRP increases tumor growth in HNSCC by suppressing TILs. Med (New York, N.Y.), 5(3), 254.

Mattar P, et al. (2024) Insulin and leptin oscillations license food-entrained browning and metabolic flexibility. Cell reports, 43(7), 114390.

Piper M, et al. (2023) Simultaneous targeting of PD-1 and IL-2R α with radiation therapy inhibits pancreatic cancer growth and metastasis. Cancer cell, 41(5), 950.

Gadwa J, et al. (2023) Selective targeting of IL2R α combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC. Cell reports. Medicine, 4(8), 101150.